- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01096602
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
June 16, 2023 updated by: Jacalyn Rosenblatt, Beth Israel Deaconess Medical Center
Acute myelogenous leukemia (AML) arises from leukemia stem cells that are difficult to eradicate and serve as a reservoir for disease relapse following chemotherapy.
A promising area of investigation is the development of immunotherapeutic approaches that stimulate the immune system to recognize leukemia stem cells as foreign and eliminate them.
The purpose of this research study is to determine the safety of the Dendritic Cell AML Fusion Vaccine (DC AML vaccine) after participants have achieved a remission with chemotherapy.
In this clinical trial, patients are treated with a tumor vaccine alone following standard of care chemotherapy.
The DC AML vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells.
It is hoped that DC AML vaccine will prevent or delay the disease from coming back.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
- On this study participants will receive the DC AML vaccine and GM-CSF 4-8 weeks after completion of chemotherapy for acute myelogenous leukemia (AML). GM-CSF is a drug that stimulates white blood cells and is given with the DC AML Vaccine in an effort to enhance the effect of the vaccine. Participants will receive 2-3 doses of the vaccine at 4 week intervals.
- All participants will undergo the following procedures: Isolation of tumor cells by either bone marrow biopsy or blood draw; Initial chemotherapy for AML with standard therapy; Leukopheresis (collection of white blood cells from the blood).
- All participants will also have blood tests, a physical exam, and an electrocardiogram prior to each dose of vaccine.
- Four weeks following the final vaccination, participants will undergo a skin test called "delayed-type hypersensitivity" (DTH). This is an injection of the tumor cells under the skin to measure how the immune system responds. The tumor cells are broken up and irradiated to prevent their growth.
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Screening:
- Patients with AML at initial diagnosis or at first relapse
- 18 years of age or older
- ECOG Performance Status 0-2
- Life expectancy of greater than 9 weeks
- Laboratory values within limits outlined in the protocol
- Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation
Prior to Cell Collections for Dendritic Cell Generation:
- Patients must have obtained complete remission with chemotherapy defined by the absence of circulating blasts, and less then 5% blasts on bone marrow examination following hematopoietic recovery
- Resolution of all chemotherapy related Grade III-IV toxicity as per CTC criteria 4.0
- Laboratory values as outlined in the protocol
- For patients with evidence of minimal residual disease prior to vaccination, assessment of minimal residual disease status by cytogenetics or FISH will be followed post vaccination
Prior to Post-Chemotherapy Immunotherapy:
- Resolution of all chemotherapy related grade III-IV toxicity
- Laboratory values as outlined in the protocol
- At least 2 doses of fusion vaccine produced
Exclusion Criteria:
Screening:
- Active or history of autoimmune disorders/conditions including Type 1 diabetes. Type II diabetes, vitiligo or stable hyperthyroidism will not be considered exclusion criteria
- HIV positive
- Significant cardiac disease characterized by symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia
- Pregnant women
- Individuals with a history of a different malignancy are ineligible except for circumstances outlined in the protocol document
Prior to Cell Collection for Dendritic Cell Generation:
- Serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
- Patients who choose to proceed with allogeneic or autologous transplant at the time of remission will not be vaccinated and will come off study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
DC AML Fusion Vaccine
|
Group 1: 2-3 doses of the vaccine at 4 week intervals
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity
Time Frame: 2 years
|
To assess the toxicity associated with treating AML patients with DC/AML fusion cells in the post-chemotherapy setting
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune Response
Time Frame: 2 years
|
To explore immunological response to DC/AML fusion vaccination in patients who have achieved a chemotherapy-induced remission.
|
2 years
|
T-cell and Immune Response
Time Frame: 2 years
|
To correlate levels of circulating activated and regulatory T cells with immunologic response
|
2 years
|
Disease Response
Time Frame: 2 years
|
To define anti-tumor effects by determining time to disease progression.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jacalyn Rosenblatt, MD, Beth Israel Deaconess Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Estimated)
December 1, 2023
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
March 29, 2010
First Submitted That Met QC Criteria
March 30, 2010
First Posted (Estimated)
March 31, 2010
Study Record Updates
Last Update Posted (Estimated)
June 19, 2023
Last Update Submitted That Met QC Criteria
June 16, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-412
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AML
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Carbiogene Therapeutics Co. Ltd.Zhejiang Provincial People's HospitalRecruiting
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting
-
Glycostem Therapeutics BVRecruiting
-
Etan OrgelAstellas Pharma Global Development, Inc.No longer available
-
Chinese PLA General HospitalNavy General Hospital, BeijingCompleted
-
University Hospital Inselspital, BerneWithdrawn
-
Turkish Leukemia Study GroupCompleted
Clinical Trials on DC AML Vaccine
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; CelgeneRecruitingAcute Myelogenous LeukemiaUnited States
-
Ludwig-Maximilians - University of MunichCompleted
-
King's College LondonKing's College Hospital NHS TrustUnknownMyelodysplastic Syndromes | Leukemia, Myeloid, Acute
-
Edward HirschowitzNational Cancer Institute (NCI)CompletedVaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung CancerLung CancerUnited States
-
Baylor Research InstituteTerminatedMalignant Melanoma Stage IVUnited States
-
The Second Hospital of Shandong UniversityShandong Sunstem Biotechnology Co.,Ltd.Unknown
-
Huashan HospitalRecruiting
-
Pawel KalinskiNational Cancer Institute (NCI)CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
Affiliated Hospital to Academy of Military Medical...RecruitingAcute Myeloid LeukemiaChina
-
Zwi BernemanKom Op Tegen Kanker; Research Foundation Flanders; Stichting tegen KankerActive, not recruitingAcute Myeloid LeukemiaBelgium